Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

  • 0 views
  • 20 Jun, 2022
  • 1 location
Safety of Oral Micronized Progesterone Versus Norethisterone Acetate in Continuous Combination With Oral Estrogen as Menopausal Hormone Therapy - a Double-blind Randomized Study- PROBES Study (Progesterone Breast Endometrial Safety Study)

surrogate markers. Mammographic breast density is a strong risk factor for breast cancer, and endometrial hyperplasia is a strong risk factor for endometrial cancer. The primary objective is to compare the

  • 0 views
  • 22 Oct, 2022
  • 1 location
Longitudinal Follow-up in Women With Endometrial Hyperplasia Without Atypia

This study will prospectively enroll a total of 1000 patients (200 per year) simple hyperplasia/complex hyperplasia (SH/CH) without atypia. All subjects will receive education for exercise and weight control and be randomized 1:1 to with or without metformin intervention. At the end of this 3-year project, an interim analysis will …

  • 0 views
  • 11 Apr, 2022
  • 1 location
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia

The purpose of this research study is to compare the uterus tissue of women who receive an intrauterine system to treat their endometrial hyperplasia with the uterine tissue of women who receive

dilation and curettage
progesterone
atypical endometrial hyperplasia
megestrol acetate
levonorgestrel
  • 0 views
  • 04 Oct, 2022
  • 1 location
Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia

This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to

cancer
hyperplasia
hormone therapy
progesterone
progestin
  • 2 views
  • 30 Oct, 2021
  • 1 location
GnRHa + Letrozole vs Diane-35 + Metformin in Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

cancer
conservative treatment
adjunctive treatment
megestrol acetate
uterine disease
  • 0 views
  • 04 Oct, 2022
  • 1 location
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.

endometrial hyperplasia
histological diagnosis
atypical endometrial hyperplasia
immunohistochemistry
mirena
  • 49 views
  • 28 Feb, 2022
  • 1 location
Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy

This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from …

cancer
serum pregnancy test
atypical endometrial hyperplasia
megestrol acetate
megestrol
  • 2 views
  • 24 Oct, 2022
  • 1 location
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

body mass index
conservative treatment
atypical hyperplasia
megestrol acetate
mirena
  • 0 views
  • 08 Jul, 2022
  • 1 location
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system (LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.

atypical hyperplasia
body mass index
levonorgestrel
  • 0 views
  • 26 Mar, 2022
  • 1 location